Supercharge Your Innovation With Domain-Expert AI Agents!

Anti-IL-13 antibody

A technology of antibodies and human antibodies, applied in the fields of antibodies, anti-tumor drugs, anti-animal/human immunoglobulins, etc.

Inactive Publication Date: 2019-05-28
SHENZHEN FORWARD PHARMA LTD CO
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, IL-13 inhibitors may prevent disease progression by inhibiting the proliferation of malignant Reed-Sternberg cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-IL-13 antibody
  • Anti-IL-13 antibody
  • Anti-IL-13 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0144] Example 1 Determination of the affinity of anti-human IL-13 antibody by ELISA method

[0145] Firstly, the 96-well ELISA plate was incubated with 50 μl of 1 μg / ml streptavidin overnight at 4° C., and incubated with 250 μl of blocking solution (3% BSA in TBST) at 37° C. for 2 hours, and then the plate was washed 3 times with PBST. Add 50 μl of biotin-labeled human IL-13 (1 μg / ml) to each ELISA experiment well, and incubate for 1 hour, then wash the plate 3 times with PBST. The antibody to be tested was serially diluted 5 times from 2 μg / ml, with a total of 8 concentration points (including the blank control), and the serially diluted antibody was added to the ELISA well, incubated at 37°C for 1 hour, and then washed with PBST 3 times. Add HRP-conjugated secondary antibody and incubate at 37°C for 1 hour. Finally, wash the plate 3 times with PBST and add 50 μl TMB to react for 15 minutes. The color reaction can be terminated with 1N hydrochloric acid (50μl), and the abs...

Embodiment 2

[0148] Example 2 Determination of Anti-human IL-13 Antibody Affinity Analysis by BIAcore

[0149] The affinity of FWB1303, FWB1309, FWB1311, FWB1312, FWB1313, and FWB1316 as human IgG4 to human IL-13 was measured by surface plasmon resonance technique using BIAcore 2000 Biosensor (BIAcore AB). Briefly, antibodies were coupled to CM5 sensor chips using an amine conjugation kit (BIAcore) with a surface density of approximately 500 Ru, and serial dilutions (50 nM-0.78 nM ) through the sensor chip surface. Kinetic data were obtained by evaluating the sensor recordings obtained above using BIA Evaluation 3.1 software.

[0150] The results are shown in the table below

[0151]

Embodiment 3

[0152] Example 3 Drug efficacy of IL13 antibody in mouse asthma model

[0153] This example evaluates the in vivo pharmacodynamic study of FWB1313 on the human recombinant IL-13-induced Balb / c mouse respiratory response model.

[0154] 29 mice were divided into 5 groups, respectively

[0155] 1. G1) Naive, n=5;

[0156] 2.G2) IL-13+IgG group, 3mpk, n=8;

[0157] 3.G3) IL-13+tralokinumab group (Tralo), 3mpk, n=8;

[0158] 4.G4) IL-13+FWB1313 group, 3mpk, n=8;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides anti-IL-13 antibody and application thereof in diagnosis and treatment of IL-13 associated disorders.

Description

technical field [0001] The present invention relates to specific binding members, in particular human anti-IL-13 antibody molecules, especially those human antibody molecules that neutralize the activity of IL-13. The invention further relates to the use of anti-IL-13 in the diagnosis or treatment of IL-13 related disorders including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma Antibody Molecule Method. Background technique [0002] Preferred embodiments of the invention employ the antibody VH and / or VL domains of the antibody molecules referred to herein as FWB1311, FWB1312, FWB1313 and other antibody molecules in the repertoire defined herein. A further aspect of the invention provides compositions comprising the specific binding members of the invention, and their use in methods of inhibiting or neutralizing IL-13, including methods of treating the human or animal body by specific therapies. [0003] As indica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/24A61K39/395A61P11/06A61P17/00A61P11/02A61P1/00A61P35/00A61P37/08A61P1/16
Inventor 朱程刚徐良亮付晓李刚洲
Owner SHENZHEN FORWARD PHARMA LTD CO
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com